Recognizing and Treating HFpEF: How Helpful Are MRAs, ARNi and SGLT2 Inhibitors for Treating Patients? What Have We Learned From The PARADIGM and PARAGON Trials?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

Confirm Password

About Us
Team
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Recognizing and Treating HFpEF: How Helpful Are MRAs, ARNi and SGLT2 Inhibitors for Treating Patients? What Have We Learned From The PARADIGM and PARAGON Trials?

By San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians FEATURING Barry Greenberg

February 5, 2021

0 Comments

A Treatment Option for Heart Failure Patients With Reduced Ejection Fracti…

Feat. B. Hilkert, B. Colucci

11th Annual Multimodality Cardiovascular Imaging for the Clinician

Sat, Dec 11, 2021

Northwestern Medicine Cardiovascular Care

17th Annual Heart Failure Holiday Symposium

Fri, Dec 10, 2021

64:45

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

Primer on Diabetes Management

Feat. S. Inzucchi

18:43

ASPC 2019 Congress on CVD Prevention

Diabetes Treatment Guidelines Finally Have Entered the 21st Century - Almo…

Feat. R. DeFronzo

26:01

Cardiology Fiesta 2017

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibition

Feat. R. DeFronzo

27:24

Cardiometabolic Health Congress (CMHC)

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Feat. L. Sloan

14:44

26th Annual San Diego Heart Failure Symposium

Broadening Indications for the Use of Angiotensin Receptor Neprilysin Inhi…

Feat. C. Yancy

13:07

Michelle Kittleson

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - How to…

21:28

Keck School of Medicine of USC

Takotsubo Syndrome: What Diagnostic Criteria Are Available? Which Drugs to…

Feat. H. Van Herle

33:02

Houston Methodist DeBakey Heart and Vascular Center

Acute Heart Failure and Cardiogenic Shock

Feat. A. Bhimaraj

12:23

American Heart & Vascular Institute

SGLT2 Inhibitors for HF: Is this Therapy Helpful for Reducing the Hospital…

Feat. M. Tipton

11:50

American Heart & Vascular Institute

New Medications for Heart Failure: SGLT2 Inhibitors and Vericiguat. Where …

Feat. M. Kittleson

64:40

Cardiac Contractility Modulation

CCM® Therapy - Mechanism of Action, Patient Selection and Identification

Feat. A. Kaplan, H. Saltzman

63:10

Cardiac Contractility Modulation

Failure Is not an Option! Implementing CCM into your Practice

Feat. F. Syed, M. Goldschmidt, I. Rao

88:01

Cardiac Contractility Modulation

The Comparison and Advantages of the Use of Device Therapy in Heart Failur…

Feat. V. Thohan, G. Tomassoni, R. Doshi, F. Abi-Samra, I. Rao

24:58

Boston Scientific

How to Manage HF using a Remote Heart Failure Diagnostic and Monitoring So…

Feat. J. Boehmer

05:10

Boston Scientific

HeartLogic™: The First FDA-Approved Predictive Analytic Alert in an Implan…

Feat. A. Hernandez, J. Boehmer, J. Singh, C. Fier, N. Albert

61:12

Cardiac Contractility Modulation

Assessing Heart Failure Patients - Where Does CCM® Therapy Fit

Feat. S. Brune, N. Bonnet, M. Arnold

16:54

Cardiac Contractility Modulation

Cardiac Contractility Modulation: How it Works

Feat. J. Ehrlich, H. Levin

27:33

Boston Scientific

Multi-Sensor Heart Failure Monitoring: What Are the Benefits of HeartLogic…

Feat. J. Boehmer

13:42

George Bakris

Current Status of Prevention and Treatment of Diabetic Nephropathy

33:38

Cardiac Contractility Modulation

AAHFN Advanced 2020 - CCM® in HF - Mechanism and Clinical Evidence

Feat. R. Kahwash, N. Albert

Login

Login

Join VuMedi

Recognizing and Treating HFpEF: How Helpful Are MRAs, ARNi and SGLT2 Inhibitors for Treating Patients? What Have We Learned From The PARADIGM and PARAGON Trials?

Related Content